SNDL INC (SNDL)

CA83307B1013 - Common Stock

1.83  0 (0%)

Premarket: 1.83 0 (0%)

Fundamental Rating

3

SNDL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SNDL have multiple concerns. While showing a medium growth rate, SNDL is valued expensive at the moment.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

SNDL had negative earnings in the past year.
SNDL had a negative operating cash flow in the past year.
SNDL had negative earnings in each of the past 5 years.
SNDL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SNDL's Return On Assets of -11.72% is fine compared to the rest of the industry. SNDL outperforms 71.94% of its industry peers.
With a decent Return On Equity value of -14.25%, SNDL is doing good in the industry, outperforming 78.06% of the companies in the same industry.
Industry RankSector Rank
ROA -11.72%
ROE -14.25%
ROIC N/A
ROA(3y)-16.37%
ROA(5y)-36.28%
ROE(3y)-18.99%
ROE(5y)-54.06%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SNDL has a Gross Margin (23.54%) which is comparable to the rest of the industry.
SNDL's Gross Margin has improved in the last couple of years.
SNDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.95%
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNDL has more shares outstanding than it did 1 year ago.
SNDL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SNDL is higher compared to a year ago.

2.2 Solvency

SNDL has an Altman-Z score of 1.05. This is a bad value and indicates that SNDL is not financially healthy and even has some risk of bankruptcy.
SNDL has a Altman-Z score of 1.05. This is in the better half of the industry: SNDL outperforms 60.71% of its industry peers.
SNDL has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
SNDL has a Debt to Equity ratio (0.11) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 1.05
ROIC/WACCN/A
WACC7.24%

2.3 Liquidity

A Current Ratio of 3.94 indicates that SNDL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.94, SNDL is in line with its industry, outperforming 56.63% of the companies in the same industry.
SNDL has a Quick Ratio of 2.69. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.69, SNDL perfoms like the industry average, outperforming 48.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.94
Quick Ratio 2.69

More info and screens

6

3. Growth

3.1 Past

SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.46%, which is quite impressive.
SNDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.01%.
SNDL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 146.22% yearly.
EPS 1Y (TTM)55.46%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40.2%
Revenue 1Y (TTM)31.01%
Revenue growth 3Y146.22%
Revenue growth 5YN/A
Revenue growth Q2Q3.35%

3.2 Future

Based on estimates for the next years, SNDL will show a very strong growth in Earnings Per Share. The EPS will grow by 29.73% on average per year.
Based on estimates for the next years, SNDL will show a quite strong growth in Revenue. The Revenue will grow by 10.55% on average per year.
EPS Next Y105.08%
EPS Next 2Y47.29%
EPS Next 3Y45.52%
EPS Next 5Y29.73%
Revenue Next Year7.91%
Revenue Next 2Y8.88%
Revenue Next 3Y8.9%
Revenue Next 5Y10.55%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SNDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 164.50, which means the current valuation is very expensive for SNDL.
Based on the Price/Forward Earnings ratio, SNDL is valued a bit cheaper than the industry average as 77.04% of the companies are valued more expensively.
SNDL is valuated expensively when we compare the Price/Forward Earnings ratio to 21.27, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 164.5

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SNDL is valued a bit cheaper than 73.98% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 184.23

4.3 Compensation for Growth

SNDL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as SNDL's earnings are expected to grow with 45.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.29%
EPS Next 3Y45.52%

More info and screens

0

5. Dividend

5.1 Amount

SNDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SNDL INC

NASDAQ:SNDL (4/18/2024, 7:20:48 PM)

Premarket: 1.83 0 (0%)

1.83

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap476.70M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 164.5
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.72%
ROE -14.25%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 23.54%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.94
Quick Ratio 2.69
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)55.46%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y105.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)31.01%
Revenue growth 3Y146.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y